Impact of Stopping Ozempic on Type 1 Diabetes Management

Overview

A recent study has highlighted the effects of halting semaglutide, marketed as Ozempic, in adults with type 1 diabetes. Findings suggest that discontinuation leads to a notable decline in time spent within the target blood glucose range, alongside increased glycemic variability.

Key Findings

Data from the ADJUST-T1D extension study indicates that individuals who ceased using semaglutide experienced a median decline of 3.6 percentage points in their time in range three months post-discontinuation. In contrast, those who were on a placebo saw a median increase of 1.5 percentage points during the same period.

The study further reported a significant rise in glycemic variability for the semaglutide group compared to the placebo group. Specifically, the glucose standard deviation changed by a mean of 6 mg/dL for the semaglutide group, versus just 1.2 mg/dL in the placebo group. Similarly, the coefficient of variation increased by an average of 3.1 percentage points for those who had stopped semaglutide, compared to a 1.1 percentage point increase for the placebo group.

Context of the Research

Initially, the ADJUST-T1D trial showcased improvements in multiple glucose monitoring metrics in adults who received semaglutide over a period of 26 weeks. This post hoc extension study aimed to evaluate the metrics three months following the end of the treatment, involving 58 of the original 72 participants.

According to Dr. Kanchan Bhasin, a postdoctoral fellow at Indiana University, the results indicate that while semaglutide offers substantial benefits to adults with type 1 diabetes, including enhanced glycemic control and reduced insulin needs, these improvements may not endure once the medication is ceased.

Clinical Implications

The findings underline the necessity for healthcare providers to monitor their patients closely after they stop semaglutide. It is essential for clinicians to reassess insulin regimens and glucose monitoring data promptly during this transitional phase.

Dr. Bhasin emphasized the importance of counseling for individuals with type 1 diabetes that not all benefits experienced during treatment with semaglutide may continue after discontinuation. She reiterated that semaglutide should not be viewed as an alternative to insulin therapy, but rather as a complementary approach.

Future Directions

Dr. Bhasin calls for further research, proposing that larger studies with extended follow-up periods are crucial for understanding the consequences of stopping semaglutide in the type 1 diabetes demographic. She is also involved in the ATT1D study, which investigates the efficacy and safety of GLP-1 receptor agonists and SGLT2 inhibitors for individuals with type 1 diabetes.

This investigation aims to provide deeper insights into the long-term effects of such therapies and their roles in diabetes management.